**Name of Journal: *World Journal of Gastrointestinal Endoscopy***

**ESPS Manuscript NO: 19909**

**Manuscript Type: MINIREVIEWS**

**Treatment of gastric outlet obstruction that results from unresectable gastric cancer: Current evidence**

Miyazaki Y *et al.* Current treatments for gastric outlet obstruction

**Yasuhiro Miyazaki, Shuji Takiguchi, Tsuyoshi Takahashi, Yukinori Kurokawa, Tomoki Makino, Makoto Yamasaki, Kiyokazu Nakajima, Masaki Mori, Yuichiro Doki**

**Yasuhiro Miyazaki, Shuji Takiguchi, Tsuyoshi Takahashi, Yukinori Kurokawa, Tomoki Makino, Makoto Yamasaki, Kiyokazu Nakajima, Masaki Mori, Yuichiro Doki,** Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita-shi, Osaka 565-0871, Japan

**Author contributions:** Miyazaki Y, Takiguchi S, Nakajima K, Mori M and Doki Y designed the research; Miyazaki Y, Takiguchi S, and Takahashi T performed the research; Kurokawa Y, Makino T and Yamasaki M contributed analytic tools; Kurokawa Y analyzed the data; Miyazaki Y wrote the paper.

Conflict-of-interest statement: The authors declare there is no conflict of interest for this article.

**Open-Access**: This article is an open-access article, which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to**: **Shuji Takiguchi, MD,** Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2-E2, Yamadaoka, Suita, Osaka 565-0871, Japan. stakiguchi@gesurg.med.osaka-u.ac.jp

**Telephone:** +81-6-68793251

**Fax:** +81-6-68793259

**Received:** May 25, 2015

**Peer-review started:** May 27, 2015

**First decision:** August 31, 2015

**Revised:** October 2, 2015

**Accepted:** December 13, 2015

**Article in press:**

**Published online:**

**Abstract**

Malignant gastric outlet obstruction (GOO) is a common condition that results from locally advanced malignancies in the upper gastrointestinal tract, such as pancreatic, gastric, and other carcinomas. Two types of procedures for malignant GOO, namely, gastrojejunostomy (GJ) with laparotomy or a laparoscopic approach and endoscopic stenting (ES), are currently available. Although numerous previous reports have clarified the benefits and drawbacks of each procedure, whether GJ or ES should be used in patients with GOO that results from gastric cancer who may have a longer life expectancy than patients with other malignancies has not been determined. In this review, which focuses on gastric cancer-induced GOO, we analyzed the two systematic reviews and a meta-analysis that compared GJ and ES and outlined the current status of GOO treatment. We also provide an updated review that includes laparoscopic GJ. Various data from 13 studies in one review and 6 studies in another review were analyzed. Although the main results of the present review indicated that both GJ and ES were efficacious treatments in patients with GOO that resulted from gastric cancer, current evidence suggests that GJ may be the preferable procedure given its good performance status and improved prognosis in gastric cancer patients.

**Key words:** Gastric outlet obstruction; Gastrojejunostomy; Endoscopic stenting; Gastric cancer; Review

**© The Authors 2015**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Both gastrojejunostomy (GJ) and endoscopic stenting (ES) are effective treatments in patients with gastric outlet obstruction that results from gastric cancer. The advantages of GJ include fewer late complications and a long patency, whereas the advantages of ES include better short-term outcomes, including the length of the hospital stay. Although no large-scale randomized clinical trials have compared the safety and efficacy of the two procedures, this present literature review indicates the superiority of GJ compared with ES given its good performance status and improved prognosis in gastric cancer patients as well as the widespread use of the less invasive laparoscopic GJ procedure.

Miyazaki Y, Takiguchi S, Takahashi T, Kurokawa Y, Makino T, Yamasaki M, Nakajima K, Mori M, Doki Y. Treatment of gastric outlet obstruction that results from unresectable gastric cancer: Current evidence. *World J Gastrointest Endosc* 2015; In press

**INTRODUCTION**

Malignant gastric outlet obstruction (GOO) is a clinical symptom of advanced malignancies in the upper gastrointestinal tract, most commonly pancreatic and gastric malignancies. Other causes include lymphomas, ampullary carcinomas, biliary tract cancers, and metastases[1-3]. Associated symptoms, including nausea, vomiting, reflux, malnutrition, dehydration, and abdominal distention, reduce patient quality of life (QOL), and patients with malignant GOO often present with a poor condition and performance status (PS)[4]. Furthermore, palliative treatment is important and required for patients with unresectable primary malignancies or metastatic lesions.

 Treatments for malignant GOO include gastrojejunostomy (GJ), which is traditionally adopted, and palliative endoscopic stenting (ES), which is considered less invasive with a faster improvement of oral intake compared with GJ[5]. Recently, the use of palliative ES has increased[6]. In addition, various types of stents are now available, and the procedure has been established and advocated[7-11]. However, the disadvantages of ES include a high rate of stent re-obstruction and migration as late complications, and pleural treatment is required with some frequency[2].

 Many comparative trials of GJ and ES in patients with malignant GOO have been performed to evaluate the safety, feasibility, costs, and patient QOL. However, to date, the available data regarding “gastric cancer” patients with GOO who could theoretically have a longer life expectancy than patients with other malignancies are not sufficient to definitively conclude the comparative benefits and limitations of GJ and ES. In this review, we outline the current status of GJ and ES treatment for malignant GOO, especially in gastric cancer, and provide a future perspective.

**STUDY STRATEGY**

***Data source and search strategy***

An increasing number of studies regarding ES, including novel devices, has been reported during the past decade, especially in the most recent five years; thus, the outcome of GJ should be compared with recent ES. Literature searches of the electronic PubMed and Embase databases were performed. The searches were limited to articles published from January 2010 to December 2014 in English as well as human- and clinical trial-related articles to identify objective articles from January 2010 to December 2014. The following terms were utilized: “Gastric outlet obstruction”, “GOO”, “gastric cancer”, and “gastric carcinoma”. The abstracts were reviewed, and articles not related to the specific content were excluded. Duplicate references and repeated articles were also excluded. All articles considered eligible were selected, and the final selection was based on the full research papers.

***Study selection***

We included review articles, studies that reported randomized and controlled trials or experimental studies, and case studies. Articles were first screened and selected based on the titles. The full text was obtained for 45 articles.

**MALIGNANT GOO THAT RESULTS FROM OF GASTRIC CANCER**

Despite a decrease in the incidence of gastric cancer over previous decades, gastric cancer remains the fourth most common malignant disease and the second main cause of cancer-related death worldwide[12]. To date, the curative resection ratio for newly diagnosed gastric cancer is approximately 50%, and 20% to 30% of patients with gastric cancer present with stage IV disease[13,14].

 Malignant GOO is a common condition among locally advanced gastric cancer patients and can lead to significant morbidity, including nausea, vomiting, abdominal pain, dehydration, malnutrition, and weight loss. Not surprisingly, these clinical symptoms have a negative impact on QOL[15]. To avoid the disastrous consequences of malignant GOO, appropriate treatment is indispensable, which enables not only an amelioration of the patient’s QOL but also the commencement of chemotherapy, including essential oral agents, such as S1 or capecitabine[16]. These treatments are included in the first-line regimen for unresectable gastric cancer recommended in the Japanese gastric cancer treatment guidelines[17].

GJ is traditionally the palliative treatment of choice for patients with malignant unresectable GOO, whereas the palliative endoscopic treatment of GOO with endoluminal self-expanding metallic stents has only recently become available. Both treatments have benefits and limitations associated with prognosis; thus, it is important to determine the optimal treatment approach. Although GOO may occur with other malignancies, such as pancreatic periampullary carcinoma, lymphoma, and metastases to the duodenum of jejunum[1-3], GOO in gastric cancer should be considered separately. First, gastric cancer has a longer life expectancy than other biological malignancies, and more chemotherapy agents have been developed for this malignancy compared with other diseases[18-20]. Second, GOO that results from gastric cancer has a reduced possibility of co-occurring with an obstruction of the bile duct compared with biliopancreatic malignancies. Several studies have reported a median overall survival of 13 mo for unresectable or recurrent gastric carcinoma[21], which is longer than pancreatic cancer (6.7-8.5 mo)[22].

 Therefore, the decision regarding whether to select GJ or ES should depend on the condition and PS of patients. Furthermore, prior to any procedure, information regarding the benefits and drawbacks of GJ and ES is necessary for well-informed consent.

**TREATMENTS FOR GASTRIC OUTLET OBSTRUCTION**

***GJ***

Traditionally, GOO caused by malignancy is treated with a palliative “open” GJ (OGJ), which is surgically performed[23]. Although this modality has a favorable outcome and relieves many symptoms derived from GOO, it results in some morbidity and mortality given the poor condition of these patients[1,24]. Several recent studies have reported the effectiveness of “laparoscopic” GJ (LGJ) with regard to safety, feasibility, and invasiveness; however, its role has not been clarified[25,26]. Jeurnink *et al*[5]reported that LGJ appears to be more favorable regarding tolerable oral administration, the duration of the hospital stay, and the complication ratio compared with OGJ. However, no significant differences were identified between the two approaches[27]. Navarra *et al*[28] also published a randomized controlled trial (RCT) that compared LGJ and OGJ (*n* = 12 patients each). LGJ resulted in significantly less intra-operative blood loss, a shorter time to tolerating solid food intake, and a reduced rate of complications; however, no significant difference was identified in the postoperative hospital stay[28]. In contrast, older retrospective studies have reported benefits with regard to intra-operative blood loss and hospital stay as well as a high conversion rate to OGJ[29,30]. Different outcomes of LGJ have been reported, and this variation can be explained by the small sample sizes and low power. However, no clinical trials with sufficient power have demonstrated the effectiveness of LGJ compared with OGJ, and LGJ is now the preferred standard for malignant GOO treatment[31].

***ES***

Endoscopic treatment of GOO with endoluminal self-expanding metallic stents was first described by Topazian *et al*[6] in the early 1990s. Over the previous decade, experiences and reports of the use of ES have increased. In addition, various types of upper gastrointestinal stents have become available, and well-established ES procedures have been advocated and performed[32]. Recently, several articles have reported that patients who present with GOO with a long life expectancy should undergo ES given its safety, minimal invasiveness, and cost-effectiveness[33]. Self-expandable metallic stents (SEMSs) are the standard devices for recanalization of an obstructed digestive lumen. However, some SEMSs exhibit re-occlusion because of tumor in growth through openings between the stent wire filaments or stent migration as late major complications[34]. Covered SEMSs prevent ingrowth through the mesh wall, and they are advantageous compared with uncovered SEMSs in esophageal cancer[35]. However, in malignant colorectal obstruction, covered stents do not exhibit an advantage compared with uncovered stents due to high migration rates[36]. Several studies have also suggested that covered stents are associated with more frequent re-intervention despite approximately similar outcomes and complications in malignant GOO. Therefore, with regard to ES for GOO, the effectiveness and complications of covered and uncovered SEMSs in patients with GOO have recently been highlighted. Kim *et al*[37] reported a prospective RCT of covered versus uncovered stents for the palliation of GOO in gastric cancer patients and concluded that the overall stent patency did not differ between the two groups; moreover, frequent migration of the covered SEMSs offsets its advantages in the prevention of re-stenosis. Maetani *et al*[38] also reported similar results in a multicenter randomized trial in Japan, *i.e.*, no significant difference in the stent patency between triple-layered covered and uncovered metallic stents for the palliation of malignant GOO; however, the use of a triple-layered covered SEMS was associated with less frequent stent dysfunction more than 4 wk after the initial stent. Regardless of the stent configuration, covered or uncovered, the ES procedure for GOO caused by malignancy is considered safe and efficacious.

**RECENT SYSTEMATIC REVIEW AND COMPARATIVE RESEARCH OF TREATMENTS FOR GOO THAT RESULTS FROM GASTRIC CANCER**

***Two systematic reviews***

Two systematic reviews and a meta-analysis that compared GJ and ES have been published since 2010. In review 1 in 2010, Ly *et al*[27] performed a comprehensive search of the literature for the period from 1990 to 2008 using Medline, EMBASE, Google Scholar, ISI Proceedings, the Cochrane Library, and online registers of CCTs but not PubMed. This review included only clinical studies that directly compared GJ and ES for the palliative treatment of GOO, which included randomized clinical trials (RCTs) and prospective and retrospective cohort comparison studies. Thirteen studies were analyzed, including 10 retrospective cohort comparison studies[1,26,39-46], 1 prospective study[41], and 2 RCTs[25,47]. In review 2 in 2012, Zheng *et al*[48]searched the PubMed, Embase, Chinese Biomedical Database (CBM), and Cochrane Library for all studies between 1996 and 2010. The inclusion criteria were as follows: controlled clinical trials (CCTs) and RCTs; analyses of “both” GJ (OGJ and LGJ) and ES; any sample size; full paper; and not a duplicate report. Six studies remained in the final analysis, including three RCTs[25,47,49] and three CCTs[41,50,51]. Both reviews included the same two studies. One study was a RCT reported by Mehta *et al*[25] in 2006, and the other study was a CCT reported by Johnsson *et al*[41] in 2004.

 Table 1 provides the characteristics of the comparative data and main results for GJ and ES in the two reviews with regard to the study type, primary tumor site, number of procedures, and favorable procedure group with better results regarding: (1) the number of patients who tolerated oral intake; (2) time to oral intake (days); (3) length of hospital stay (days); and (4) complications. Ninety-four (18.2%) of 514 patients and 55 (28.6%) of 192 patients with GOO that resulted from “gastric cancer” were included. Technical success was only documented in Review 2, and GJ exhibited greater technical success than ES [odds ratio (OR) = 0.10, 95% confidence interval (CI) = 0.02-0.47, *I2*= 0%, *P* = 0.0039] according to a meta-analysis. However, the significant difference remained only in the non-RCT group. Nevertheless, both GJ and ES demonstrated satisfactory results regarding technical success (success rates of 99 to 100% and 8 to 100%, respectively). The ability to tolerate oral intake after palliative treatments for GOO is one of the most important endpoints and was documented as a “clinical success” in Review 2. With regard to the ability to tolerate oral intake, 11 studies included in Review 1 reported more favorable results following ES compared with GJ. Although no significant difference was identified in the two studies included in Review 2, one study reported that ES was associated with greater clinical success than GJ (*P =* 0.007). Regarding the time to oral intake after the palliative procedure, all reported data in both reviews indicated that ES had clear merits compared with GJ. The average time from the procedure to the initiation of oral intake was approximately 3 d less for ES compared with GJ. Several studies have evaluated the length of hospital stay and medical costs. All studies reported a significantly reduced hospital stay for patients who underwent ES compared with GJ (mean difference of 12 d). One RCT and one CCT demonstrated reduced total medical costs and hospital stay costs with ES compared with GJ. In summary, approximately all studies indicated that ES has advantages compared with GJ. However, cost should not be the main factor in decisions regarding procedures for malignant GOO patients because the costs per day for patients who consumed at least a soft diet were quite similar between both procedures. Better long-term clinical outcomes after GJ compared with ES were noted in the major prospective randomized SUSTENT study, which was included in Review 2[52].

 Both reviews indicated that there are no significant differences in the major complication rates between GJ and ES (OR = 1.04, 95%CI = 0.47-2.29, *P* = 0.93 according to meta-analysis data in Review 1; OR = 3.76, 95%CI = 0.57-24.72, *P* = 0.17 in Review 2). The detailed major medical complications that result from GJ were reported as respiratory tract infections, myocardial infarction, and acute renal failure, whereas the complications of ES were procedure-related, including stent failure migration and obstruction. Although minor complications were described only in Review 2, they were less likely the result of ES compared with GJ (OR = 0.28, 95%CI = 0.10-0.83, *P* = 0.02). Regarding morality, both reviews indicated similar conclusions indicating no differences between the two treatments (OR = 0.58, 95%CI = 0.18-1.86, *P* = 0.36).

 The length of survival was estimated in both reviews. Despite the inclusion of both randomized and non-RCT, no significant difference was identified between GJ and ES (mean difference 26 d; 95%CI = 69.03-16.40 d, *P* = 0.23 in Review 1).

**DISCUSSION**

***Comparative studies between GJ and ES for malignant GOO that results from gastric cancer***

One non-randomized prospective study[53] and two retrospective studies[54,55] are available regarding malignant GOO caused by limited unresectable or metastatic gastric cancer. Table 2 provides patient demographics and the main results of three studies with regard to study type, number of procedures, PS, and the favorable procedure group with better results regarding: (1) the number of patients who tolerated oral intake; (2) time to oral intake (d); (3) length of hospital stay (d); and (4) complications.

In a prospective study of 18 patients (9 OGJ and 9 ES treatment)[53], ES had more favorable results regarding the mean time to resume oral feeding (3.1 d) and mean length of hospital stay (4.8 d) compared with GJ (6.3 d and 10 d, respectively). Regarding the late results, such as the recurrence of GOO, late complications due to the procedure, overall survival, and patient satisfaction, no significant differences were identified between OGJ and ES. Recurrent symptoms of GOO were evident only in ES (*n* = 3 patients, 33%) due to stent migration and obstruction of the stent by food. Both procedures resulted in sufficient patient satisfaction.

In their retrospective study, No *et al*[54] concluded that GJ is preferable to ES for the palliation of GOO that results from gastric cancer in patients with a good PS, especially Eastern Cooperative Oncology Group (ECOG) 0 to 1. In this study, 72 ES and 41 GJ (32 OGJ and 9 LGJ) patients were compared regarding patient demographics, early outcomes and adverse events, late adverse events, patency duration, and survival. The two groups did not differ in most characteristics with the exception of sex (more men in the GJ group). The technical success rates in both groups were excellent (ES: 95.8% *vs* GJ: 97.6%); however, three technical failures were noted in the ES group. However, the time to oral intake was significantly less in the ES group compared with the GJ group (liquid diet: ES 2 d *vs* GJ 5 d, solid diet: ES 10 d *vs* GJ 16 d). Regarding adverse events, a higher rate of late adverse events was identified in the ES group compared with the GJ group (44.4% *vs* 12.2%, *P* < 0.01), whereas early adverse events were not significantly different between the two groups. The adverse events in the ES group were not significantly different according to the stent type (*P =* 0.158). Similarly, the number of re-interventions was significantly greater in the ES group compared with the GJ group (31 (43%) *vs* 4 (5.5%), respectively, *P* < 0.001). Regarding the patency duration, the median duration of both the first stent patency and total stent patency, including the patency achieved by an additional stent, was 210 d shorter in the ES group compared with the GJ group (*P* = 0.001, *P* = 0.044,respectively*)*. The interesting finding in this previous study was the analysis according to PS (ECOG status). Patients in the GJ group exhibited significantly longer overall survival compared with the ES group, but only for ECOG 0 to 1.

Keränen *et al*[55] compared three palliative methods, including 50 ES, 26 palliative resections of the stomach (PR), and 21 GJ. All palliative surgeries were performed with laparotomy. Patients with ES presented with the poorest general condition among all groups in terms of the pre-procedure albumin level, PS, and amount of oral intake; thus, the ES group exhibited the worst survival. The main results regarding the palliation of GOO symptoms demonstrated that ES resulted in a faster improvement of oral intake, relief of GOO symptoms, and reduced hospital stay compared with GJ. The authors advocated considering how the clinical condition before treatment affects survival in malignant GOO that results from gastric cancer when determining the type of palliative procedures. Furthermore, the authors indicated that the study had several limitations. The study was non-randomized, retrospective, and had a certain degree of defective follow-up data, which led to selection bias between the treatment groups. However, this retrospective study reported the time between ES treatment and re-obstruction; however, this information was described only in context, not in tables or figures. The median time to re-obstruction after ES was 95 d; thus, most patients had died before re-obstruction occurred. Therefore, re-obstruction of the stent is not a major problem for patients with a poor prognosis (< 3 mo), even in patients with gastric cancer and particularly in patients with pancreatic cancer or other malignancies with a worse prognosis.

In summary, the main findings of comparative studies between GJ and ES that focused on gastric cancer patients were similar to the findings of other RCTs, CCTs, and retrospective studies of patients with GOO that resulted from malignancies other than gastric carcinoma. In addition, no articles have referred to precise cost performance or compared LGJ and ES. Compared with GJ, ES is preferred for the rapid improvement of oral intake, relief of GOO symptoms, and reduced hospital stay, whereas the occurrence of late complications, such as stent obstruction or migration, is higher. The differences compared with other malignant GOOs are patient survival after GJ or ES and patient PS. The median survival durations in these three articles were 283, 189 to 293, and 50 to 241 d. Thus, the potential survival of GOO patients with gastric cancer may be increased by approximately 2 or 3 mo. Because several studies have reported that GJ is preferable for patients with a longer life expectancy[49], GJ should be selected more frequently in clinical practice for good PS patients with GOO that results from gastric cancer.

**CONCLUSION**

Both GJ and ES are effective treatments in patients with GOO that results from gastric cancer. GJ exhibits better long-term outcomes with regard to fewer late complications and long patency, whereas ES exhibits better short-term outcomes, including the length of the hospital stay. Although no large-scale studies or RCTs have compared the safety and efficacy of the two procedures, literature reviews suggest that GJ may be the preferable procedure because of the good PS and long prognosis of gastric cancer patients.

However, the bypass procedure is currently performed laparoscopically (LGJ), and various novel devices in the ES field can minimize stent obstruction or migration. Therefore, to determine the more preferable procedure in patients with GOO that results from gastric cancer, a prospective RCT of LGJ and ES with current devices specialized for gastric cancer patients is warranted.

**REFERENCES**

1. **Del Piano M**, Ballarè M, Montino F, Todesco A, Orsello M, Magnani C, Garello E. Endoscopy or surgery for malignant GI outlet obstruction? *Gastrointest Endosc* 2005; **61**: 421-426 [PMID: 15758914 DOI: 10.1016/S0016-5107(04)02757-9]
2. **Pinto Pabón IT**, Díaz LP, Ruiz De Adana JC, López Herrero J. Gastric and duodenal stents: follow-up and complications. *Cardiovasc Intervent Radiol* ; **24**: 147-153 [PMID: 11443401 DOI: 10.1007/s002700001742]
3. **Park KB**, Do YS, Kang WK, Choo SW, Han YH, Suh SW, Lee SJ, Park KS, Choo IW. Malignant obstruction of gastric outlet and duodenum: palliation with flexible covered metallic stents. *Radiology* 2001; **219**: 679-683 [PMID: 11376254 DOI: 10.1148/radiology.219.3.r01jn21679]
4. **Lopera JE**, Brazzini A, Gonzales A, Castaneda-Zuniga WR. Gastroduodenal stent placement: current status. *Radiographics* ; **24**: 1561-1573 [PMID: 15537965 DOI: 10.1148/rg.246045033]
5. **Jeurnink SM**, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. *BMC Gastroenterol* 2007; **7**: 18 [PMID: 17559659 DOI: 10.1186/1471-230X-7-18]
6. **Topazian M**, Ring E, Grendell J. Palliation of obstructing gastric cancer with steel mesh, self-expanding endoprostheses. *Gastrointest Endosc* ; **38**: 58-60 [PMID: 1377147 DOI: 10.1016/S0016-5107(92)70334-4]
7. **Binkert CA**, Jost R, Steiner A, Zollikofer CL. Benign and malignant stenoses of the stomach and duodenum: treatment with self-expanding metallic endoprostheses. *Radiology* 1996; **199**: 335-338 [PMID: 8668774 DOI: 10.1148/radiology.199.2.8668774]
8. **Feretis C**, Benakis P, Dimopoulos C, Manouras A, Tsimbloulis B, Apostolidis N. Duodenal obstruction caused by pancreatic head carcinoma: palliation with self-expandable endoprostheses. *Gastrointest Endosc* 1997; **46**: 161-165 [PMID: 9283868 DOI: 10.1016/S0016-5107(97)70066-X]
9. **Dumas R**, Demarquay JF, Caroli-Bosc FX, Paolini O, Guenenna D, Peten EP, Delmont JP, Rampal P. [Palliative endoscopic treatment of malignant duodenal stenosis by metal prosthesis]. *Gastroenterol Clin Biol* ; **24**: 714-718 [PMID: 11011246]
10. **Espinel J**, Vivas S, Muñoz F, Jorquera F, Olcoz JL. Palliative treatment of malignant obstruction of gastric outlet using an endoscopically placed enteral Wallstent. *Dig Dis Sci* 2001; **46**: 2322-2324 [PMID: 11713929]
11. **Siddiqui A**, Spechler SJ, Huerta S. Surgical bypass versus endoscopic stenting for malignant gastroduodenal obstruction: a decision analysis. *Dig Dis Sci* 2007; **52**: 276-281 [PMID: 17160470 DOI: 10.1007/s10620-006-9536-z]
12. **Carcas LP**. Gastric cancer review. *J Carcinog* 2014; **13**: 14 [PMID: 25589897 DOI: 10.4103/1477-3163.146506]
13. **Kokkola A**, Sipponen P, Arkkila P, Danielson H, Puolakkainen P. Does the eradication of Helicobacter pylori delay the diagnosis of gastric cancer? *Scand J Gastroenterol* 2008; **43**: 1456-1460 [PMID: 18663664 DOI: 10.1080/00365520802273041]
14. **Lagman RL**, Davis MP, LeGrand SB, Walsh D. Common symptoms in advanced cancer. *Surg Clin North Am* 2005; **85**: 237-255 [PMID: 15833469 DOI: 10.1016/j.suc.2004.11.004]
15. **Adler DG**, Baron TH. Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients. *Am J Gastroenterol* 2002; **97**: 72-78 [PMID: 11808972 DOI: 10.1111/j.1572-0241.2002.05423.x]
16. **Pasini F**, Fraccon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer. *Anticancer Res* 2011; **31**: 3543-3554 [PMID: 21965776]
17. **Japanese Gastric Cancer Association**. Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer* 2011; **14**: 113-123 [PMID: 21573742 DOI: 10.1007/s10120-011-0042-4]
18. **Emoto S**, Sunami E, Yamaguchi H, Ishihara S, Kitayama J, Watanabe T. Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. *Surg Today* 2014; **44**: 2209-2220 [PMID: 24482110 DOI: 10.1007/s00595-014-0848-x]
19. **Imano M**, Okuno K. Treatment strategies for gastric cancer patients with peritoneal metastasis. *Surg Today* 2014; **44**: 399-404 [PMID: 23677598 DOI: 10.1007/s00595-013-0603-8]
20. **Yoshikawa T**, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. *Surg Today* 2014; **44**: 11-21 [PMID: 23508452 DOI: 10.1007/s00595-013-0529-1]
21. **Koizumi W**, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol* 2008; **9**: 215-221 [PMID: 18282805 DOI: 10.1016/S1470-2045(08)70035-4]
22. **Bergmann L**, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. *Eur J Cancer* 2015; **51**: 27-36 [PMID: 25459392 DOI: 10.1016/j.ejca.2014.10.010]
23. **Takeno A**, Takiguchi S, Fujita J, Tamura S, Imamura H, Fujitani K, Matsuyama J, Mori M, Doki Y. Clinical outcome and indications for palliative gastrojejunostomy in unresectable advanced gastric cancer: multi-institutional retrospective analysis. *Ann Surg Oncol* 2013; **20**: 3527-3533 [PMID: 23715966 DOI: 10.1245/s10434-013-3033-3]
24. **Bozzetti F**, Bonfanti G, Audisio RA, Doci R, Dossena G, Gennari L, Andreola S. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. *Surg Gynecol Obstet* 1987; **164**: 151-154 [PMID: 2433778]
25. **Mehta S**, Hindmarsh A, Cheong E, Cockburn J, Saada J, Tighe R, Lewis MP, Rhodes M. Prospective randomized trial of laparoscopic gastrojejunostomy versus duodenal stenting for malignant gastric outflow obstruction. *Surg Endosc* 2006; **20**: 239-242 [PMID: 16362479 DOI: 10.1007/s00464-005-0130-9]
26. **Mittal A**, Windsor J, Woodfield J, Casey P, Lane M. Matched study of three methods for palliation of malignant pyloroduodenal obstruction. *Br J Surg* 2004; **91**: 205-209 [PMID: 14760669 DOI: 10.1002/bjs.4396]
27. **Ly J**, O'Grady G, Mittal A, Plank L, Windsor JA. A systematic review of methods to palliate malignant gastric outlet obstruction. *Surg Endosc* 2010; **24**: 290-297 [PMID: 19551436 DOI: 10.1007/s00464-009-0577-1]
28. **Navarra G**, Musolino C, Venneri A, De Marco ML, Bartolotta M. Palliative antecolic isoperistaltic gastrojejunostomy: a randomized controlled trial comparing open and laparoscopic approaches. *Surg Endosc* 2006; **20**: 1831-1834 [PMID: 17063298 DOI: 10.1007/s00464-005-0454-5]
29. **Bergamaschi R**, Mårvik R, Thoresen JE, Ystgaard B, Johnsen G, Myrvold HE. Open versus laparoscopic gastrojejunostomy for palliation in advanced pancreatic cancer. *Surg Laparosc Endosc* 1998; **8**: 92-96 [PMID: 9566559 DOI: [10.1097/00019509-199804000-00002](http://dx.doi.org/10.1097/00019509-199804000-00002%22%20%5Ct%20%22_blank)]
30. **Nagy A**, Brosseuk D, Hemming A, Scudamore C, Mamazza J. Laparoscopic gastroenterostomy for duodenal obstruction. *Am J Surg* 1995; **169**: 539-542 [PMID: 7538268 DOI: 10.1016/S0002-9610(99)80213-X]
31. **Al-Rashedy M**, Dadibhai M, Shareif A, Khandelwal MI, Ballester P, Abid G, McCloy RF, Ammori BJ. Laparoscopic gastric bypass for gastric outlet obstruction is associated with smoother, faster recovery and shorter hospital stay compared with open surgery. *J Hepatobiliary Pancreat Surg* 2005; **12**: 474-478 [PMID: 16365822 DOI: 10.1007/s00534-005-1013-0]
32. **Adler DG**. Enteral stents for malignant gastric outlet obstruction: testing our mettle. *Gastrointest Endosc* 2007; **66**: 361-363 [PMID: 17643713 DOI: 10.1016/j.gie.2006.12.053]
33. **Tringali A**, Didden P, Repici A, Spaander M, Bourke MJ, Williams SJ, Spicak J, Drastich P, Mutignani M, Perri V, Roy A, Johnston K, Costamagna G. Endoscopic treatment of malignant gastric and duodenal strictures: a prospective, multicenter study. *Gastrointest Endosc* 2014; **79**: 66-75 [PMID: 23932009 DOI: 10.1016/j.gie.2013.06.032]
34. **Dormann A**, Meisner S, Verin N, Wenk Lang A. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. *Endoscopy* 2004; **36**: 543-550 [PMID: 15202052 DOI: 10.1055/s-2004-814434]
35. **Vakil N**, Morris AI, Marcon N, Segalin A, Peracchia A, Bethge N, Zuccaro G, Bosco JJ, Jones WF. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. *Am J Gastroenterol* 2001; **96**: 1791-1796 [PMID: 11419831 DOI: 10.1111/j.1572-0241.2001.03923.x]
36. **Lee KM**, Shin SJ, Hwang JC, Cheong JY, Yoo BM, Lee KJ, Hahm KB, Kim JH, Cho SW. Comparison of uncovered stent with covered stent for treatment of malignant colorectal obstruction. *Gastrointest Endosc* 2007; **66**: 931-936 [PMID: 17767930 DOI: 10.1016/j.gie.2007.02.064]
37. **Kim CG**, Choi IJ, Lee JY, Cho SJ, Park SR, Lee JH, Ryu KW, Kim YW, Park YI. Covered versus uncovered self-expandable metallic stents for palliation of malignant pyloric obstruction in gastric cancer patients: a randomized, prospective study. *Gastrointest Endosc* 2010; **72**: 25-32 [PMID: 20381802 DOI: 10.1016/j.gie.2010.01.039]
38. **Maetani I**, Mizumoto Y, Shigoka H, Omuta S, Saito M, Tokuhisa J, Morizane T. Placement of a triple-layered covered versus uncovered metallic stent for palliation of malignant gastric outlet obstruction: a multicenter randomized trial. *Dig Endosc* 2014; **26**: 192-199 [PMID: 23621572 DOI: 10.1111/den.12117]
39. **Wong YT**, Brams DM, Munson L, Sanders L, Heiss F, Chase M, Birkett DH. Gastric outlet obstruction secondary to pancreatic cancer: surgical vs endoscopic palliation. *Surg Endosc* 2002; **16**: 310-312 [PMID: 11967685 DOI: 10.1007/s00464-001-9061-2]
40. **Yim HB**, Jacobson BC, Saltzman JR, Johannes RS, Bounds BC, Lee JH, Shields SJ, Ruymann FW, Van Dam J, Carr-Locke DL. Clinical outcome of the use of enteral stents for palliation of patients with malignant upper GI obstruction. *Gastrointest Endosc* 2001; **53**: 329-332 [PMID: 11231392 DOI: 10.1016/S0016-5107(01)70407-5]
41. **Johnsson E**, Thune A, Liedman B. Palliation of malignant gastroduodenal obstruction with open surgical bypass or endoscopic stenting: clinical outcome and health economic evaluation. *World J Surg* 2004; **28**: 812-817 [PMID: 15457364 DOI: 10.1007/s00268-004-7329-0]
42. **Maetani I**, Akatsuka S, Ikeda M, Tada T, Ukita T, Nakamura Y, Nagao J, Sakai Y. Self-expandable metallic stent placement for palliation in gastric outlet obstructions caused by gastric cancer: a comparison with surgical gastrojejunostomy. *J Gastroenterol* 2005; **40**: 932-937 [PMID: 16261429 DOI: 10.1007/s00535-005-1651-7]
43. **Mejia A,** Ospina J, Munoz A, Albis R, Oliveros R. Palliation of a malignant gastroduodenal obstruction. *Rev Col Gastroenterol* 2006; **21**: 17-21
44. **Espinel J**, Sanz O, Vivas S, Jorquera F, Muñoz F, Olcoz JL, Pinedo E. Malignant gastrointestinal obstruction: endoscopic stenting versus surgical palliation. *Surg Endosc* 2006; **20**: 1083-1087 [PMID: 16703436 DOI: 10.1007/s00464-005-0354-8]
45. **Maetani I**, Tada T, Ukita T, Inoue H, Sakai Y, Nagao J. Comparison of duodenal stent placement with surgical gastrojejunostomy for palliation in patients with duodenal obstructions caused by pancreaticobiliary malignancies. *Endoscopy* 2004; **36**: 73-78 [PMID: 14722859 DOI: 10.1055/s-2004-814123]
46. **El-Shabrawi A**, Cerwenka H, Bacher H, Kornprat P, Schweiger J, Mischinger HJ. Treatment of malignant gastric outlet obstruction: endoscopic implantation of self-expanding metal stents versus gastric bypass surgery. *Eur Surg* 2006; **38**: 451-455 [DOI: 10.1007/s10353-006-0295-z]
47. **Fiori E**, Lamazza A, Volpino P, Burza A, Paparelli C, Cavallaro G, Schillaci A, Cangemi V. Palliative management of malignant antro-pyloric strictures. Gastroenterostomy vs. endoscopic stenting. A randomized prospective trial. *Anticancer Res* ; **24**: 269-271 [PMID: 15015607]
48. **Zheng B**, Wang X, Ma B, Tian J, Jiang L, Yang K. Endoscopic stenting versus gastrojejunostomy for palliation of malignant gastric outlet obstruction. *Dig Endosc* 2012; **24**: 71-78 [PMID: 22348830 DOI: 10.1111/j.1443-1661.2011.01186.x]
49. **Jeurnink SM**, Steyerberg EW, van Hooft JE, van Eijck CH, Schwartz MP, Vleggaar FP, Kuipers EJ, Siersema PD. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. *Gastrointest Endosc* 2010; **71**: 490-499 [PMID: 20003966 DOI: 10.1016/j.gie.2009.09.042]
50. **Guo JJ**, Liang WX, Zhang T. [A prospective comparative study of three treatment options in patients with malignant gastric outlet obstruction]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2010; **13**: 598-600 [PMID: 20737313]
51. **Schmidt C**, Gerdes H, Hawkins W, Zucker E, Zhou Q, Riedel E, Jaques D, Markowitz A, Coit D, Schattner M. A prospective observational study examining quality of life in patients with malignant gastric outlet obstruction. *Am J Surg* 2009; **198**: 92-99 [PMID: 19482259 DOI: 10.1016/j.amjsurg.2008.09.030]
52. **Jeurnink SM**, Polinder S, Steyerberg EW, Kuipers EJ, Siersema PD. Cost comparison of gastrojejunostomy versus duodenal stent placement for malignant gastric outlet obstruction. *J Gastroenterol* 2010; **45**: 537-543 [PMID: 20033227 DOI: 10.1007/s00535-009-0181-0]
53. **Fiori E**, Lamazza A, Demasi E, Decesare A, Schillaci A, Sterpetti AV. Endoscopic stenting for gastric outlet obstruction in patients with unresectable antro pyloric cancer. Systematic review of the literature and final results of a prospective study. The point of view of a surgical group. *Am J Surg* 2013; **206**: 210-217 [PMID: 23735668 DOI: 10.1016/j.amjsurg.2012.08.018]
54. **No JH**, Kim SW, Lim CH, Kim JS, Cho YK, Park JM, Lee IS, Choi MG, Choi KY. Long-term outcome of palliative therapy for gastric outlet obstruction caused by unresectable gastric cancer in patients with good performance status: endoscopic stenting versus surgery. *Gastrointest Endosc* 2013; **78**: 55-62 [PMID: 23522025 DOI: 10.1016/j.gie.2013.01.041]
55. **Keränen I**, Kylänpää L, Udd M, Louhimo J, Lepistö A, Halttunen J, Kokkola A. Gastric outlet obstruction in gastric cancer: a comparison of three palliative methods. *J Surg Oncol* 2013; **108**: 537-541 [PMID: 24590674 DOI: 10.1002/jso.23442]

**P-Reviewer:** Gurkan A, Huang CM, Kim JJ **S-Editor:** Kong JX **L-Editor: E-Editor:**

**Table 1 Characteristics and main results of two reviews**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Review | Year | Study type | Primary tumor | Procedure | Favorable groupregarding several variables |
| **Retro** | **Pro** | **RCT** | **Stomach** | **Pancreas** | **Others** | **GJ** | **ES** | **Toleration of oral intake1** | **Time to oral intake2****(d)** | **Hospital stay3****(d)** | **Complication** |
| 1 | 2010 | 10 | 1 | 2 | 94 (18.3%) | 240 (46.7%) | 180 (35.0%) | 255(LGJ 37) | 244 | ES | ES(2.0 d) | ES(9.4 d) | GJ is approximately equal to ES |
| 2 | 2012 | 0 | 3 | 3 | 55(28.6%) | 86 (44.8%) | 51 (26.6%) | 92(LGJ 0) | 74 | GJ(not-RCT) | ES(2.1-5.0 d) | ES(2.5-7.0 d) | Major:GJ is approximately equal to ESMinor: ES |

1Patients were more likely to tolerate oral intake following ES than GJ in Review 1; however, Review 2 reported the opposite results. The difference was only significant in the non-RCT group. **2**The mean time from the procedure to initiate oral intake was 7 d (Review 1) and 3.6 d (Review 2) less for ES compared with GJ. **3**The mean length of hospital stay was reduced by 12 d (Review 1) and 7.5 d (Review 2) for ES compared with GJ. Retro: Retrospective; Pro: Prospective; RCT: Randomized controlled trial; GJ: Gastrojejunostomy; ES: Endoscopic stenting; LGJ: Laparoscopic GJ.

**Table 2 Patient demographics and main results in two reviews**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author | Study type | Procedure | Performance Status | Comparison between GJ and ESregarding several variables |
| **GJ** | **ES** | **GJ** | **ES** | **Toleration of oral intake** | **GOO recurrence** | **Time to oral intake** | **Hospital stay** | **Complication** |
| Fiori *et al*[53] | Prospective | 9(LGJ 0) | 9 | NR | NR | GJ is approximately equal to ES | GJ (0%)< ES (33%)a | GJ(6.3 d) | GJ(10 d) | GJ: SSI, bleeding, ventral hernia |
| ES(3.1 d) | ES(4.8 d) | ES: stent dislocation, re-obstruction |
| No *et al* [54] | Retrospective | 41(LGJ 9) | 72 | 0-11:68.3% | 0-11:59.7% | GJ (95.1%)is approximately equal to ES (87.5%) | GJ (12.2%)< ES (44.4%)a | GJ (16 d) > ES (10 d)a | GJ (18 d)> ES (16 d)3 | GJ is approximately equal to ES |
| 21:31.7% | 21:40.3% |
| Keranen *et al*[55] | Retrospective | 21(LGJ 0) | 50 | I-II2:90.5% | I-II2:58% | GJ (81%)is approximately equal to ES (88%) | GJ(9.5%) | GJ (4 d) > ES (1 d)a | GJ (8 d) > ES (3 d)a | GJ(10%) |
| III-IV2:9.5% | III-IV2:42% | ES(24%) | ES(26%) |

1ECOG performance status. 2WHO score. 3Not significant. a*P* < 0.05. GJ: Gastrojejunostomy; ES: Endoscopic stenting; LGJ: Laparoscopic GJ; NR: Not reported; ECOG: Eastern Cooperative Oncology Group; WHO: World Health Organization.